Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2707PDF: 810HTML: 6491Untitled: 204Untitled: 167Untitled: 163Untitled: 186 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1151PDF: 727HTML: 295 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1129PDF: 705HTML: 1327Figure 1: 153Figure 2: 150 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2504PDF: 769HTML: 5172 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3486PDF: 830HTML: 6693 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1591PDF: 1114HTML: 227 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1513PDF: 772HTML: 136 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3103PDF: 1008HTML: 411 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2741PDF: 1531HTML: 215 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3748PDF: 723HTML: 1820 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
1941PDF: 1445HTML: 255 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
920PDF: 931Suppl. Files: 612HTML: 87 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7183PDF: 2344HTML: 1699Table 1.: 182Table 2.: 197Table 3.: 179Table 4.: 177 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
747PDF: 399HTML: 268 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1867PDF: 1323HTML: 244 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2497PDF: 699HTML: 2281 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1299PDF: 1264HTML: 77 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1409PDF: 887HTML: 207 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1120PDF: 804HTML: 3342 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1340PDF: 1002HTML: 205 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2065PDF: 1294HTML: 3485 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1146PDF: 910HTML: 187 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
533PDF: 254Suppl. Files: 101HTML: 90







